HR 220 — A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

PRINTER'S NO.   1564

                  THE GENERAL ASSEMBLY OF PENNSYLVANIA



           HOUSE RESOLUTION
              No. 220
                                              Session of
                                                2025

     INTRODUCED BY DELLOSO, WAXMAN, SCHLOSSBERG, VENKAT, HILL-EVANS,
        KAZEEM, PROBST, SANCHEZ AND NEILSON, APRIL 30, 2025

     REFERRED TO COMMITTEE ON HUMAN SERVICES, MAY 1, 2025


                               A RESOLUTION
 1   Designating the week of May 4 through 10, 2025, as "Tardive
 2      Dyskinesia Awareness Week" in Pennsylvania.
 3      WHEREAS, Many people with serious mental health conditions,
 4   such as bipolar disorder, major depressive disorder,
 5   schizophrenia and schizoaffective disorder, or with
 6   gastrointestinal disorders, including gastroparesis, upset
 7   stomach, nausea and vomiting, may be treated with medications
 8   that work as dopamine receptor blocking agents (DRBAs),
 9   including antipsychotics and antiemetics; and
10      WHEREAS, While ongoing treatment with these medications can
11   be necessary, prolonged use is associated with tardive
12   dyskinesia (TD), an involuntary movement disorder that is
13   characterized by uncontrollable, abnormal and repetitive
14   movements of the face, torso, limbs, fingers or toes; and
15      WHEREAS, Even mild symptoms of TD can impact people
16   physically, socially and emotionally; and
17      WHEREAS, It is estimated that TD affects approximately
18   800,000 people in the United States and approximately 60% of
 1   people with TD have not been diagnosed, making it important to
 2   raise awareness about the symptoms; and
 3      WHEREAS, It is important that people taking DRBA medication
 4   be monitored for TD by a health care provider; and
 5      WHEREAS, The American Psychiatric Association recommends
 6   regular screenings for TD; and
 7      WHEREAS, Clinical research has led to approval of treatments
 8   for adults with TD by the United States Food and Drug
 9   Administration; and
10      WHEREAS, Recognition and treatment of TD can make a positive
11   impact in the lives of many people experiencing psychotic and
12   mood disorders; and
13      WHEREAS, The House of Representatives wants to raise
14   awareness of TD among the public and medical community;
15   therefore be it
16      RESOLVED, That the House of Representatives designate the
17   week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness
18   Week" in Pennsylvania; and be it further
19      RESOLVED, That the House of Representatives encourage people
20   in this Commonwealth and across the United States to become
21   better informed about and aware of tardive dyskinesia.




20250HR0220PN1564                 - 2 -